ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near Philadelphia, PA, USA:

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

East Windsor, New Jersey, United States of America and 88 other locations

Locations recently updated

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Enrolling
Eczema
Atopic Dermatitis
Drug: ATI-045
Drug: Placebo

Phase 2

Aclaris Therapeutics
Aclaris Therapeutics

Philadelphia, Pennsylvania, United States and 45 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Philadelphia, Pennsylvania, United States and 83 other locations

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07275315
Other: Placebo

Phase 2

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States and 98 other locations

24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W f...

Active, not recruiting
Atopic Dermatitis
Drug: tralokinumab

Phase 4

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherap...

Enrolling
Atopic Dermatitis
Drug: Dupixent

Phase 4

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States and 540 other locations

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Enrolling
Atopic Dermatitis
Drug: Soquelitinib
Drug: Placebo

Phase 1

Corvus Pharmaceuticals
Corvus Pharmaceuticals

Philadelphia, Pennsylvania, United States and 15 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Philadelphia, Pennsylvania, United States and 555 other locations

Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib 30mg Dose
Drug: Upadacitinib 15mg Dose

Phase 3

AbbVie
AbbVie

Philadelphia, Pennsylvania, United States and 98 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems